Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case–control study

Cui Li, Min-Lin Zhou, Dan-Dan Liang, Jing-Jing Wang, Jing Yang, Cai-Hong Zeng, Zhi-Hong Liu, Hai-Tao Zhang

ABSTRACT

Objective To assess the clinical features, pathological presentations, treatments and outcomes of lupus nephritis (LN) with anti-neutrophil cytoplasmic antibody (ANCA) positivity.

Design A case–control study.

Methods Patients (n=49) were retrospectively included from Jinling Hospital in China if presenting with biopsy-proven ANCA-positive LN between 1985 and 2008. Clinicopathological characteristics and outcomes were analysed and compared with those of a control group (n=1279). We further compared treatment responses and outcomes of ANCA-positive LN patients based on the treatment issued.

Results The study included 40 women and 9 men (median age 33 years at biopsy): 38 with myeloperoxidase (MPO)-ANCA, 7 with proteinase 3 (PR3)-ANCA and 4 with double positivity. ANCA-positive LN patients exhibited higher haematuria, serum creatinine levels and systemic lupus erythematosus disease activity index scores. On pathological evaluation, class IV LN was predominant, accounting for 61.22% of cases. Light microscopy revealed significantly higher activity index and chronicity index scores, including cellular crescents, interstitial inflammation, tubular atrophy and interstitial fibrosis. ANCA-positive LN patients receiving mycophenolate mofetil as induction therapy had a higher remission rate and better renal outcomes than those receiving cyclophosphamide. During follow-up, end-stage renal disease developed in seven (14.29%) ANCA-positive LN patients, all of them were MPO-ANCA positive.

Conclusions The characteristics of ANCA-positive LN were massive haematuria and advanced renal insufficiency. We observed a higher remission rate and better prognoses when using mycophenolate mofetil than when using cyclophosphamide as induction therapy.

INTRODUCTION

Lupus nephritis (LN) is immune complex glomerular nephritis that develops as a frequent complication of systemic lupus erythematosus (SLE). Autoantibody production in SLE patients is a hallmark of the disease entity, as well as of its activity and prognosis.1

Intravenous cyclophosphamide (CYC) has been the traditional regimen for treating LN.2 However, CYC is frequently associated with severe side effects, and infections contribute to the overall mortality associated with LN. Recent studies have established mycophenolate mofetil (MMF), a selective lymphocyte antiproliferative agent, as a safe and an effective alternative to CYC for treating LN.3 Until now, steroids, CYC and MMF remain the first-line therapeutics for the treatment of LN.

Anti-neutrophil cytoplasmic antibody (ANCA) is the probable cause of a distinct form of vasculitis accompanied by necrotising granulomatosis. Based on ELISA results, the major target antigens of ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO).4 ANCA-positive LN patients have been described in case reports or small series over the last 25 years.5–22

However, due to the relatively small amount of research to date, the clinical features, pathological presentations and outcomes of ANCA-positive LN patients are not clear. Moreover, investigations that have addressed the treatment of this population
are rare. Therefore, we retrospectively summarised the clinicopathological characteristics and outcomes of ANCA-positive and ANCA-negative LN patients. Furthermore, we compared the efficacy, renal relapse rates, adverse events and outcomes between the use of MMF and CYC as induction therapies in ANCA-positive LN patients.

METHODS

Patients

Chinese patients (n=1814) with biopsy-proven LN at Jinling Hospital treated between January 1985 and December 2008 were retrospectively reviewed.23 Patients who fulfilled the following criteria were included in this study: (1) age ≥18 years, (2) met the American Rheumatologic Association criteria for the diagnosis of SLE,24 (3) biopsy-proven LN, (4) presence of ANCA positivity, (5) duration of follow-up ≥6 months and (6) complete baseline and follow-up data. Simultaneously, ANCA-negative LN patients during the same period were included as the control group and compared with the ANCA-positive LN patients.

Renal morphology

For light microscopy, we processed biopsy specimens for H&E, periodic acid-Schiff, Masson trichrome and Jones methenamine silver staining. Pathological parameters such as the activity index (AI) and chronicity index (CI) were determined using a modification of a previously reported system involving the semi-quantitative scoring of specific biopsy features.25 26 Vasculopathy was defined according to renal vascular complications of SLE.27 Biopsy specimens were reviewed and reclassified according to the 2003 International Society of Nephrology/Renal Pathology Society criteria.28 Two renal pathologists examined biopsy specimens. Differences in classifications and scores between the two were resolved by reviewing the biopsies.

Data collection

The following data were collected retrospectively at biopsy: gender, age, duration of LN, SLE disease activity index (SLEDAI), hypertension, extrarenal manifestations, 24-hour urinary protein excretion, urinary sediment inspection, serum albumin (SAlb) and serum creatinine (SCr), estimated glomerular filtration rate (eGFR), C3 and C4 levels, and ANCA specificity (tested by ELISA).

MMF was prescribed at doses of 1–2 g/day for 6 months, while CYC was administered at 0.5–0.75 g/m² body surface area once a month for 6 months. The total dose of CYC was less than 9 g. Patients who were given less CYC or MMF, Tripterygium wilfordii (TW) or other immunosuppressors were assigned to the other-regimens group. All patients received three methylprednisolone injections of 500 mg per day for 3 days followed by oral corticosteroids at doses of 0.6–0.8 mg per kilogram of body weight per day. Maintenance therapy was started at the end of induction therapy with low doses of prednisone and immunosuppressors, including azathioprine, leflunomide and TW. The primary efficacy endpoint was the total remission (TR) rate at 6 months, and the endpoint for renal outcome was end-stage renal disease (ESRD). When patients were at the end of the follow-up period, we recorded their laboratory findings at the last visit.

The following definitions were used: duration of LN, the time from LN diagnosis to the first renal biopsy; hypertension, blood pressure >140/90 mm Hg; complete remission (CR), proteinuria ≤0.4 g/24 hours with a normal SAlb level (≥35 g/L) and SCr level (<109.6 μmol/L); partial remission (PR), decline in proteinuria by >50% of the baseline value and proteinuria >0.4 g/24 hours but <3.5 g/24 hours, with a normal SCr level or an elevation of <15% above the baseline value, without extrarenal activity; TR, CR or PR; renal relapse, proteinuria ≥1.0 g/24 hours in patients with CR or proteinuria ≥2.0 g/24 hours in patients with PR, with or without active urine sediment or an increase in SCr by ≥30%; ESRD, eGFR <15 mL/min/per 1.73 m², initiation of dialysis therapy continued for >3 months or kidney transplantation.29 eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration 2009 creatinine equation.30 Disease activity was assessed based on the SLEDAI.31

Statistical analysis

All data were analysed using the statistical software SPSS V.17.0 (IBM). Quantitative data are presented as the mean±SD or median with the IQR. All parameters were compared using a χ² test or Fisher’s test for categorical data and a t-test, Mann-Whitney U, Kruskal-Wallis or one-way analysis of variance tests were used for continuous data. Kaplan-Meier curves and log-rank tests were used to analyse renal survival. p<0.05 was considered significant.

RESULTS

Patient information

Among the 1814 cases, 486 were not tested for ANCA specificity, 1279 showed ANCA negativity and 49 (3.69%) showed ANCA positivity, including 38 with MPO-ANCA positivity, 7 with PR3-ANCA positivity and 4 with double specificity, 1279 showed ANCA negativity and 49 (3.69%) showed ANCA negativity and 49 (3.69%) showed ANCA negativity.

ANCA-positive LN patients had higher haematuria (median 101 (IQR 25–525) vs 43 (IQR 5–176)×10⁴/μL; p=0.006), higher levels of SCr (median 91.05 (IQR 74.26–147.63) vs 73.37 (IQR 54.81–101.66) μmol/L; p<0.001) and higher SLEDAI scores (median 14 (IQR 12–18) vs 12 (IQR 10–16); p<0.001) than the controls. Conversely, there were no significant differences in the incidence of hypertension, duration of LN, sex, age, proteinuria, SAlb or serum C3 and C4 levels between the two groups (table 1).
The observed extrarenal manifestations are summarised in table 2. We did not note any differences when comparing LN patients with and without ANCA positivity.

Renal morphology

The renal biopsy findings are shown in table 3. Among the 49 ANCA-positive LN patients, 30 (61.22%) presented with class IV (including 20 (40.82%) with class IV-G and 10 with 20.41% class IV-S), 9 (18.37%) with class III, 4 (8.16%) with class IV+V, 3 (6.12%) with class V, 2 (4.08%) with class III+V and only 1 (2.04%) with class II.

On renal pathological evaluation, the scores for cellular crescents, interstitial inflammation, tubular atrophy and interstitial fibrosis among the ANCA-positive LN patients were higher than those for the control group (p=0.001, p=0.002, p=0.005 and p=0.005, respectively). Furthermore, the ANCA-positive LN patients had higher AI and CI scores (p=0.023 and p=0.010, respectively).

Treatment regimens and response

Among the 49 ANCA-positive LN patients, 20 received MMF as induction therapy, 18 received CYC and 11 were in the other-regimens group. (Details of the therapies are described in the online supplementary file 1.) We further compared data for baseline characteristics, efficacy, renal relapse rates and adverse events between the MMF and CYC groups.

---

### Table 1 Clinical and laboratory features based on ANCA specificity

|                      | ANCA (+) (n=49) | ANCA (-) (n=1279) | p Value |
|----------------------|-----------------|-------------------|---------|
| Men                  | 9 (18.37)       | 181 (14.15)       | 0.408   |
| Age, years           | 33 (26–40)      | 30 (22–37)        | 0.116   |
| Duration of LN, months | 3.77 (1.18–15.97) | 5.27 (1.80–22.20) | 0.186   |
| SLEDAI, score        | 14 (12–18)      | 12 (10–16)        | <0.001  |
| Hypertension         | 15 (30.61)      | 363 (28.38)       | 0.734   |
| Proteinuria, g/24 hours | 2.81 (1.11–5.04) | 2.29 (1.12–4.35) | 0.247   |
| Urinary RBC count, ×10⁴/mL | 101 (25–525)    | 43 (5–176)        | 0.006   |
| SAlb, g/L            | 27.40 (21.55–32.65) | 27.90 (22.40–33.40) | 0.492   |
| SCr, μmol/L          | 91.05 (74.26–147.63) | 73.37 (54.81–101.66) | <0.001  |
| eGFR, mL/min/per 1.73m² | 68.67 (44.01–96.86) | 98.36 (65.48–122.60) | <0.001  |
| <60 mL/min/per 1.73m² | 21 (42.86)      | 21 (42.86)        | 0.001   |
| <30 mL/min/per 1.73m² | 4 (8.16)        | 112 (8.76)        | 0.900   |
| C3, g/L              | 0.42 (0.34–0.66) | 0.47 (0.36–0.68)  | 0.181   |
| C4, g/L              | 0.09 (0.06–0.16) | 0.11 (0.06–0.17)  | 0.457   |

Values are given as n (%) or median (IQR).

ANCA, anti-neutrophil cytoplasmic antibody; C3, complement 3; C4, complement 4; eGFR, estimated glomerular filtration rate; LN, lupus nephritis; RBC, red blood cell; SAlb, serum albumin; SCr, serum creatinine; SLEDAI, systemic lupus erythematosus disease activity index.

### Table 2 Extrarenal manifestations based on ANCA specificity

|                      | ANCA (+) (n=49) | ANCA (-) (n=1279) | p Value |
|----------------------|-----------------|-------------------|---------|
| Fever (non-infectious) | 13 (26.53)    | 465 (36.36)     | 0.160   |
| Malar rash           | 21 (42.86)     | 711 (55.59)     | 0.079   |
| Photosensitivity     | 3 (6.12)       | 39 (3.05)       | 0.199   |
| Mouth ulcer          | 6 (12.24)      | 129 (10.09)     | 0.624   |
| Alopecia             | 8 (16.33)      | 233 (18.22)     | 0.736   |
| Arthritis            | 26 (53.06)     | 814 (63.64)     | 0.132   |
| Serositis            | 8 (16.33)      | 245 (19.16)     | 0.621   |
| Neurological disorder | 3 (6.12)      | 52 (4.07)       | 0.452   |
| Raynaud phenomenon   | 4 (8.16)       | 142 (11.10)     | 0.646   |
| Anaemia              | 36 (73.47)     | 775 (60.59)     | 0.070   |
| Leucopenia           | 9 (18.37)      | 245 (19.16)     | 0.890   |
| Thrombocytopenia     | 14 (28.57)     | 336 (26.27)     | 0.720   |

Values are given as n (%).

ANCA, anti-neutrophil cytoplasmic antibody.
Table 3 Pathological findings based on ANCA specificity

|                         | ANCA (+) (n=49) | ANCA (−) (n=1279) | p Value |
|-------------------------|-----------------|-------------------|---------|
| Number of glomeruli     | 25 (20–31)      | 23 (17–30)        | 0.250   |
| AI score                | 8.31±4.36       | 6.83±4.67         | 0.023   |
| Endocapillary hypercellularity | 1.61±1.17       | 1.62±1.26         | 0.972   |
| Karyorrhexis/fibrinoid necrosis | 0.57±0.54       | 0.44±0.50         | 0.097   |
| Cellular crescents      | 1.31±1.03       | 0.85±0.85         | 0.001   |
| Subendothelial hyaline deposits | 0.57±0.94       | 0.73±0.97         | 0.221   |
| Glomerular leucocyte infiltration | 1.00±1.10       | 0.83±0.99         | 0.302   |
| Interstitial inflammation | 1.37±0.70       | 1.08±0.67         | 0.002   |
| CI score                | 2.92±2.23       | 2.12±1.96         | 0.010   |
| Glomerular sclerosis    | 0.69±0.77       | 0.55±0.68         | 0.207   |
| Tubular atrophy         | 1.00±0.74       | 0.71±0.67         | 0.005   |
| Fibrous crescents       | 0.22±0.42       | 0.15±0.37         | 0.110   |
| Interstitial fibrosis   | 1.00±0.74       | 0.71±0.67         | 0.005   |
| Vasculopathy            |                 |                   |         |
| Hyaline degeneration of artery | 5 (10.20)       | 151 (11.81)       | 0.900   |
| Noninflammatory necrotising vasculopathy | 2 (4.08) | 69 (5.39) | 0.900   |
| Inflammatory necrotising vasculopathy | 1 (2.04) | 2 (0.16) | 0.107   |
| Thrombotic microangiopathy | 1 (2.04)       | 73 (5.71)         | 0.518   |
| Atherosclerosis         | 11 (22.45)      | 434 (33.93)       | 0.095   |

Values are given as n (%) or mean±SD. AI, activity index; ANCA, anti-neutrophil cytoplasmic antibody; CI, chronicity index.

The baseline characteristics of the study population are summarised in online supplementary table S1. All the baseline characteristics were comparable between the two groups with the exception of cellular crescent scores, which were significantly higher in the MMF group (p=0.007).

Patients receiving MMF had a higher TR rate (15 (75.00%) vs 6 (33.33%); p=0.021) and CR rate (13 (65.00%) vs 3 (16.67%); p=0.004) than those receiving CYC, as shown in table 4. Furthermore, patients receiving MMF exhibited lower levels of proteinuria (p=0.001), haematuria (p=0.083) and SCr (p=0.011) and had lower SLEDAI scores (p=0.015) and higher levels of SAlb (p=0.013) at the last follow-up. We noticed that the two groups had similar renal relapse rates.

During follow-up, 12 (60%) subjects in the MMF group and 12 (66.67%) in the CYC group reported at least one adverse event (p=0.671). Both groups had equal occurrence rates of infections, arthralgia, arthritis necrosis, menstrual disorders or menolipsis, cardiac vascular diseases, tumours and epilepsy. (table 4)

Outcomes

During follow-up (median 100.17 (IQR 51.82–186.20) months), ESRD developed in 7 (14.29%) ANCA-positive LN patients, all of those were MPO-ANCA positive, including six with class IV and one with class III LN. The renal survival rates for ANCA-positive LN patients were 97.90% at 1 year, 95.70% at 5 years and 92.30% at 10 years; these values were similar to those of the ANCA-negative LN patients, which were 97.30%, 92.50% and 87.00%, respectively (figure 1A).

The renal survival rate for ANCA-positive LN patients receiving MMF as induction therapy was 100% at 1 year, 100% at 5 years and 100% at 10 years; these values were higher than for those receiving CYC, which were 94.40%, 88.10% and 78.40%, respectively (p=0.039) (figure 1B).

DISCUSSION

ANCA positivity rates range from 0% to 30% in LN.5–22 In this study, we found that ANCA positivity was rare in LN patients and accounted for only 3.69% of the total number of biopsy-proven LN cases, which is lower than shown in other studies. This may be explained by the fact that only the biopsy-proven LN patients were included and those without a biopsy were excluded.

This study shows that ANCA-positive LN presents with unique features. First, childbearing women were predominant, with ANCA-positive LN characterised by massive haematuria and advanced renal insufficiency, similar to what has been shown in previous studies.5 7–10 Second, it was not surprising that ANCA-positive LN patients had significantly higher proportions of crescents and higher AI and CI scores. These results were partly in accordance with a previous report.8 Nasr found that all biopsies from 10 ANCA-positive LN patients exhibited prominent...
### Table 4  Treatment responses and follow-up data based on induction therapies

|                                | Total (n=49)   | MMF group (n=20) | CYC group (n=18) | The other-regimens group (n=11) | p Value* |
|--------------------------------|----------------|------------------|------------------|---------------------------------|----------|
| Follow-up time, months         | 100.17 (51.82–186.20) | 149.88 (97.47–191.53) | 96.35 (25.36–169.06) | 81.60 (34.90–119.90) | 0.114    |
| Treatment response             |                |                  |                  |                                 |          |
| Complete remission             | 22 (44.90)     | 13 (65.00)       | 3 (16.67)        | 6 (54.55)                       | 0.004    |
| Partial remission              | 27 (55.10)     | 15 (75.00)       | 6 (33.33)        | 6 (54.55)                       | 0.021    |
| Total remission                | 27 (55.10)     | 15 (75.00)       | 6 (33.33)        | 6 (54.55)                       | 0.021    |
| Renal relapse                  | 8 (29.63)      | 5 (33.33)        | 2 (33.33)        | 1 (16.67)                       | 0.900    |
| Clinical data at the last follow-up |          |                  |                  |                                 |          |
| SLEDAI, score                  | 2 (0–6)        | 2 (0–4)          | 4 (2–11)         | 2 (0–5)                         | 0.015    |
| Proteinuria, g/24 hours        | 0.39 (0.79–1.06) | 0.28 (0.13–0.49) | 1.06 (0.43–3.53) | 0.25 (0.18–0.49)               | 0.001    |
| Urinary RBC count, ×10⁹/mL     | 1 (1–6)        | 1 (1–5)          | 5 (1–51)         | 1 (1–2)                         | 0.083    |
| SAlb, g/L                      | 41.00 (36.00–44.10) | 43.50 (39.18–45.10) | 35.75 (33.13–42.05) | 43.1 (40.75–45.25)          | 0.013    |
| SCr, μmol/L                    | 76.02 (54.80–113.15) | 68.95 (53.26–91.72) | 109.17 (74.92–260.12) | 50.39 (42.43–71.16)          | 0.011    |
| Adverse events                 |                |                  |                  |                                 |          |
| Infection                      | 29 (59.18)     | 12 (60.00)       | 12 (66.67)       | 5 (45.45)                       | 0.671    |
| Arthralgia                     | 9 (18.37)      | 3 (15.00)        | 3 (16.67)        | 3 (27.27)                       | 0.900    |
| Arthrosis necrosis             | 2 (4.08)       | 0 (0.00)         | 2 (11.11)        | 0 (0.00)                        | 0.218    |
| Menstrual disorder or menolipsis | 10 (20.41)  | 6 (30.00)        | 3 (16.67)        | 1 (9.09)                        | 0.454    |
| Cardiac vascular disease       | 0 (0.00)       | 0 (0.00)         | 0 (0.00)         | 0 (0.00)                        | 0.900    |
| Tumour                         | 1 (2.04)       | 0 (0.00)         | 0 (0.00)         | 1 (9.09)                        | 0.900    |
| Epilepsy                       | 2 (4.08)       | 1 (5.00)         | 1 (5.56)         | 0 (0.00)                        | 0.900    |

Values are given as n (%) or median (IQR).

*Comparison of MMF with CYC in the treatment of ANCA-positive LN patients.

CYC, cyclophosphamide; MMF, mycophenolate mofetil; RBC, red blood cell; SAlb, serum albumin; SCr, serum creatinine; SLEDAI, systemic lupus erythematosus disease activity index.
necrosis and crescents, with rare endocapillary proliferation and subendothelial deposits.\(^6\) In our study, the scores for endocapillary hypercellularity and subendothelial deposits in ANCA-positive LN patients were lower than the scores in the control group. This difference, however, was not statistically significant. ANCA-positive LN included all types of proliferative LN, and classes IV and III were predominant, similar to results shown in previous studies.\(^6\)–\(^8\)\(^12\)\(^17\)\(^19\)\(^21\)\(^32\)\(^33\)

Opinions differ about whether ANCA positivity has any association with SLEDAI scores.\(^7\)\(^10\)\(^12\)\(^17\)\(^19\)–\(^21\) In our study, ANCA-positive LN patients had higher SLEDAI scores, which might be associated with higher haematuria owing to aggravated kidney injuries caused by ANCA. However, we did not observe any differences in extrarenal manifestations between cases of LN with and without ANCA positivity.

Because of the low frequency of ANCA-positive LN, there are no well-established treatment methods for patients with this disease.\(^5\)\(^8\)\(^9\)\(^18\) Nasr showed that 6 of 10 patients reached complete or near-complete remission with CYC treatment.\(^8\) In patients who did not respond well to CYC, rituximab was administered and provided satisfactory results.\(^5\) Most authors, including us, have suggested aggressive immunosuppressive therapy.\(^5\)\(^8\) In our study, patients receiving MMF as induction therapy had higher remission rates than those receiving CYC. The relative specificity for activated lymphocytes, as well as antiproliferative and antifibrotic actions, may be responsible for the beneficial effects of MMF in treating ANCA-positive LN.\(^34\)–\(^36\)

ESRD developed in seven ANCA-positive LN patients, all of whom were MPO-ANCA positive; this phenomenon can be explained by the following two factors: first, MPO-ANCA is more common in Asia, including China.\(^37\)\(^38\) Second, several recent studies have reported worse renal survival in ANCA-associated vasculitis (AAV) patients positive for MPO-ANCA,\(^39\)–\(^41\) and MPO-ANCA positivity is most likely related to smouldering disease, which causes ESRD.\(^42\) Overall, LN patients with MPO-ANCA positivity need more attention, and a larger study is needed to find the differences between MPO-ANCA- and PR3-ANCA-positive LN patients. We believed that ANCA-positive LN patients would have worse renal outcomes; however, we could not draw this conclusion from this study.

Further detailed analysis of ANCA-positive LN patients revealed that only four had a history of taking propylthiouracil (PTU). It has been reported that 15%–64% of patients with PTU develop serum ANCA positivity, of whom 4%–6.5% have clinical symptoms of vasculitis.\(^43\)\(^44\) Of note, one patient in our study had a history of silicon exposure, which has been associated with AAV. Hogan proposed that high levels of exposure to silica dust are associated with ANCA-associated small vessel vasculitis.\(^45\) However, ANCA-positive LN was rarely induced in patients by silica exposure or PTU. Additionally, ANCA positivity in LN could result from inflammatory bowel disease and the use of levamisole and hydralazine.\(^10\) Separate analysis is needed of all the possible causes of ANCA positivity related to conditions such as inflammatory bowel disease, silicon exposure and the use of levamisole, hydralazine and PTU. We will continue this research and analyse more patients in future studies.

A putative pathogenic mechanism for vascular inflammation begins with ANCA-induced activation of primed neutrophils and monocytes, leading to the activation of the alternative complement pathway. Based on a deeper understanding of the pathogenesis of SLE, the increased cell death and enhanced extracellular trap formation observed in SLE-derived neutrophils might play key roles in the induction of autoimmunity and the development of organ damage.\(^46\) It has been suggested that LN might facilitate the process of ANCA formation by promoting neutrophil degranulation and priming neutrophils,
increasing the surface expression of ANCA, including that of MPO-ANCA and PR3-ANCA. We observed that 28.57% of ANCA-positive LN patients did not exhibit crescents, and we concluded ANCA might participate in the development of crescents in LN as a major pathogenic mechanism in a gradual process and that the ANCA titre and duration of ANCA positivity would affect the formation of crescents.

There are some limitations to the findings of this report. First, all patients included in this study were of Chinese Han ethnicity; therefore, our results may not completely apply to non-Asians. Second, due to the limitations of a retrospective study, our conclusions require further validation.

In conclusion, the characteristics of ANCA-positive LN were massive haematuria and advanced renal insufficiency. We observed a higher remission rate and better prognoses when using MMF than when using CYC as induction therapy.

Contributors All authors contributed significantly to this manuscript, including contributions in the study design (CL and HTZ), chart reviews (CL, MLZ, DDL, ZHL and HTZ), interpretation of the data (CL, MLZ, DDL and HTZ) and preparation of the manuscript (CL, MLZ, DDL, JY, CHZ, ZHL and HTZ).

Funding This study was supported by the National Key Technology Research and Development Program (No. 20113BAD08B04 and No. 2015BAI22B05) and the Jiangsu Provincial Clinical Science and Technology Project (No BL2012007).

Competing interests None declared.

Ethics approval Jinling Hospital, Nanjing University School of Medicine, China.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement We will not share data.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357–66.
2. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–9.
3. Rath M, Goyal A, Jaryal A, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 2016;89:335–42.
4. Hilhorst M, van Paasen P, Verraert JW, et al. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 2015;26:2314–27.
5. Bobek D, Vukovic J, Malenica B, et al. Anti-neutrophil cytoplasmic antibody positivity in five children with systemic lupus erythematosus—what is the importance of this finding? Acta Dermatovenerol Croat 2014;22:264–70.
6. Hervier B, Hamidou M, Haroche J, et al. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int 2012;32:3285–90.
7. Pan HF, Fang XH, Wu GC, et al. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation 2008;31:260–5.
8. Nasr SH, D’Agati VD, Park HR, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008;3:682–90.
9. Erdoğan O, Oner A, Demirci G, et al. A boy with concurrent development of SLE and Wegener granulomatosis. Pediatr Nephrol 2004;19:438–41.
10. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003;12:515–20.
11. Manolova I, Dancheva M, Balacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int 2000;20:197–204.
12. Qin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol 2000;20:57–63.
13. Faure-Fontenla MA, Rodriguez-Suarez RS, Arias-Velazquez R, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus in childhood. J Rheumatol 1999;26:2490–1.
14. Arahata H, Migita K, Iizomo H, et al. Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clin Rheumatol 1999;18:77–81.
15. Zhao MH, Liu N, Zhang YK, et al. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant 1998;13:2821–4.
16. Galeazzzi M, Morozzi G, Sebastiani D, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 1998;16:541–6.
17. Nishita K, Chikazawa H, Nishimura S, et al. Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Clin Rheumatol 1997;16:70–5.
18. Marshall S, Dressier R, D’Agati V. Membranous nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Am J Kidney Dis 1997;29:119–24.
19. Schnabel A, Csernok E, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis & Rheumatism 1995;38:633–7.
20. Pauzner R, Urowitz M, Gladman D, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol 1994;21:1670–3.
21. Lee SS, Lawton JW, Chan CE, et al. Anti-neutrophil antibody in systemic lupus erythematosus. Br J Rheumatol 1992;31:669–73.
22. Wang Y, Huang X, Cai J, et al. Clinopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody. Medicine 2016;95:e2580–8.
23. Yang J, Jiang D, Zhang H, et al. Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 2015;24:1468–78.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism 1997;40:40.
25. Austin HA, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544–50.
26. Austin HA, Muenzer JR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1994;25:689–95.
27. Appel GB, Pirani CL, D’Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994;4:1499–515.
28. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521–30.
29. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904–10.
30. Levey AS, Schmid LS, Dobson AJ, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.
31. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis & Rheumatism 1992;35:10–2.
32. Sinico RA, Pozzi C, Radice A, et al. Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases. Am J Kidney Dis 1993;22:253–60.
33. Tang Y, Zhang X, Ji L, et al. Clinopathological and outcome analysis of adult lupus nephritis patients in China. Int Urol Nephrol 2015;47:513–20.
34. Dall’Era M, Sahin A. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2011;23:454–8.
35. Tang Y, Zhang G, Yu C, et al. Effects of mycophenolate mofetil for patients with crescentic lupus. Nephrol Dial Transplant 2008;23:702–7.
36. Huang Y, Liu Z, Huang H, et al. Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005;5:1029–39.
37. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. *Rheumatology* 2011;50:1916–20.

38. Chen M, Yu F, Zhang Y, et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. *Medicine* 2008;87:203–9.

39. Tanna A, Guarino L, Tam FW, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. *Nephrol Dial Transplant* 2015;30:1185–92.

40. Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. *J Rheumatol* 2014;41:1366–73.

41. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. *Clin J Am Soc Nephrol* 2013;8:1709–17.

42. Franssen CF, Stegeman CA, Oost-Kort WW, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. *J Am Soc Nephrol* 1998;9:1915–23.

43. Chen M, Gao Y, Guo XH, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. *Nat Rev Nephrol* 2012;8:476–83.

44. Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. *Nephrology* 2009;14:33–41.

45. Hogan SL, Satterly KK, Dooley MA, et al. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. *J Am Soc Nephrol* 2001;12:134–42.

46. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nat Rev Rheumatol* 2014;10:463–73.

47. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. *Nat Rev Rheumatol* 2011;7:691–9.